Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meteoroid: Satralizumab in MOGAD
NCT05271409Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2022
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of satralizumab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), sponsored by Roche. Started Aug 2022; status: active, not recruiting.
02
Drugs
satralizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on NCT05271409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271409.